FDA Questions Efficacy of Merck-AstraZeneca’s Lynparza Ahead of Adcomm

In briefing documents published ahead of the Oncologic Drugs Advisory Committee (ODAC) meeting, FDA staffers argued that Merck and AstraZeneca’s Lynparza (olaparib) is effective in only a subset of patients with metastatic castration-resistant prostate cancer (mCRPC).